Triastek has been named to J.P. Morgan Private Bank's 'Top 100 Women-Powered, High-Growth Businesses in Asia Pacific'


We are very proud to announce that Triastek has been named to the "Top 100 Women-Powered, High-Growth Businesses in Asia Pacific" report released in March 2023 by J.P. Morgan Private Bank.

The report which studied "women-powered" businesses across major Asia-Pacific markets – where women are founders or co-founders, or hold C-suite management positions, highlights the changes seen in the region, identifies and carefully analyzes high-growth women-driven businesses, and gives people a better understanding of the role of women in the economy.

Part of the Top 100 Rankings in the Report

High-growth businesses refer to private companies that have secured significant funding in recent years and have potential to raise more capital for future growth. Founded in 2015, Triastek have raised over $100 million capital from renowned investors. Current investors include: Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, and Triwise Capital.

Leader Profile of Dr. Senping Cheng, Founder and CEO of Triastek in the Report

Founded and managed by Dr. Senping Cheng, Triastek is one of two companies that dominate 3D printing pharmaceutical industry globally. Compared to conventional drug development and production, the 3D printing technology allows small-scale production of medicines which paves the way for personalized therapies. The 3D printing technology uses raw materials more efficiently which eliminates toxic and non-toxic waste. Dr. Senping Cheng said, "Triastek is such a challenging adventure with unlimited application potential, therefore I fully devote myself to making it successful. I can foresee the tremendous value it will bring to the pharmaceutical industry and to the world. "

As a technology-platform-driven enterprise in the pharmaceutical industry, Triastek is committed to build a transparent organization and have an employee-centric culture to attract the best people to join our mission. "We need very creative scientists and engineers across multiple disciplines because our business is innovation-driven. At least one-third of my time goes into convincing people to join Triastek," explained Dr. Senping Cheng.

Dr. Senping Cheng hopes more women in society could be encouraged to embrace entrepreneurship. "Women like us need to be role models. But the power to promote women's development comes not only from entrepreneurs, but also from the whole society. The right trend is observed, especially in big cities like Shanghai and Nanjing," she added.

About Triastek

Triastek, Inc. is a global healthcare company, developing medicines with proprietary, pioneering 3D printing technology. Triastek is dedicated to revolutionizing the delivery, development and manufacturing of pharmaceutical products by unlocking the next generation of medicine through the use of 3D printing technology. Its state-of-the-art technology, called Melt-Extrusion Deposition (MED®), facilitates the development of medicines with complex structures to enable controlled and precise release of treatments. Since 2021, three products independently developed by Triastek, T19, T20 and T21, have successfully obtained clinical trial approval (IND) from the US FDA.

Copyright © 2024 (TRIASTEK)

Contact Us

Follow us on


COPYRIGHT © 2024 TRIASTEK. 苏ICP备17053162号